和铂医药-B(02142)今日盘中大涨5.05%,市场关注度显著提高。
消息面上,和铂医药近期公告拟行使购回授权,根据市况不时于公开市场购回最多4000万港元的公司股份。该计划体现了公司管理层对未来业务增长的信心,也彰显了公司提升股东价值的决心。公司目前资金充足,能在维持稳健财务状况下实施股份回购。
同时,和铂医药全资子公司诺纳生物与Candid就开发下一代T细胞衔接器达成一项研究合作及授权协议。根据协议条款,诺纳生物有权获得首付款及潜在里程碑付款最高达3.2亿美元,这为公司注入了新的增长动力。市场普遍看好该项目的前景,预期公司未来将获得可观收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.